Overview

Glyphic Biotechnologies is advancing proteomics by building a next-generation protein sequencing platform. The core product is designed to reveal detailed information about proteins, helping researchers and medical institutions gain new insights into biology and disease. The platform supports sequencing services for researchers and may be licensed to other organizations, generating revenue from service fees and licensing agreements. Unlike many competitors that focus on smaller-scale tools, Glyphic emphasizes a first-of-its-kind sequencing capability for proteins, along with diverse deployment options (serving research labs directly and via licensing). The company's goal is to enable deeper understanding of bodily functions through protein data and to bring its sequencing technology to broader use in the life sciences through services and licensing deals.